Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
FALCO HOLDINGS Co., Ltd. (4671.T)
Kyoto, JP
FALCO HOLDINGS Co., Ltd., a medical services enterprise established in 1962 and headquartered in Kyoto, Japan, primarily delivers clinical diagnostic testing and pharmaceutical dispensing solutions. The company serves medical institutions and various corporations throughout Japan. Its comprehensive range of clinical testing encompasses specialized areas such as genetics, biochemistry, hematology, pathology, immunology, microbiology, and radioimmunoassay. Beyond direct diagnostics, FALCO HOLDINGS also engages in genomic-based drug discovery and the development of biotechnological pharmaceuticals. The company's offerings extend to medical information technology services, as well as environmental and food sanitation testing. They also provide genetic testing tailored for the food industry, catering to manufacturers, retailers, and restaurants. Additionally, FALCO HOLDINGS operates dispensing pharmacies and drugstores. They are also active in the development and sale of medical information systems, notably including "@home Dr.," an electronic medical record system designed for clinics with a high volume of clinical testing, and "TASCAL for ASP," a robust medical support system.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.07% | +5.14% | +1.88% | -2.10% | +4.16% | -1.19% | +14.87% | +31.34% | +54.21% | +97.40% | +105.97% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+0.6% Q1'26: +2.0% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+10.6% Q1'26: +13.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+3.5% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+5.7% Q1'26: +7.0% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+9.2% ★ Q1'26: +11.3% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-5.1% ★ Q1'26: -2.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.35× ★ Q1'26: 0.30× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
45.97B
est: 46.50B (-1.1%)
|
45.96B
est: 45.70B (+0.6%)
|
44.16B
est: 44.15B (+0.0%)
|
43.19B
est: 43.20B (0.0%)
|
43.61B
est: 42.90B (+1.7%)
|
50.01B
est: 49.40B (+1.2%)
|
46.91B
est: 46.50B (+0.9%)
|
43.01B
est: 43.00B (+0.0%)
|
43.31B
est: 42.80B (+1.2%)
|
43.20B
43.20B – 43.20B
+0.9% YoY
|
43.60B
43.60B – 43.60B
+0.9% YoY
|
| EBITDA |
3.02B
est: 4.56B (-33.6%)
|
3.09B
est: 4.48B (-31.0%)
|
2.17B
est: 4.33B (-50.0%)
|
1.78B
est: 4.23B (-58.1%)
|
3.88B
est: 4.20B (-7.8%)
|
6.55B
est: 4.84B (+35.3%)
|
4.76B
est: 4.56B (+4.3%)
|
3.56B
est: 4.21B (-15.5%)
|
3.72B
est: 4.19B (-11.2%)
|
4.23B
4.23B – 4.23B
+0.9% YoY
|
4.27B
4.27B – 4.27B
+0.9% YoY
|
| EBIT |
2.24B
est: 3.56B (-37.0%)
|
2.21B
est: 3.50B (-36.7%)
|
1.21B
est: 3.38B (-64.1%)
|
1.87B
est: 3.30B (-43.5%)
|
2.92B
est: 3.28B (-10.9%)
|
5.59B
est: 3.78B (+48.1%)
|
3.71B
est: 3.56B (+4.4%)
|
2.58B
est: 3.29B (-21.5%)
|
2.78B
est: 3.27B (-15.0%)
|
3.30B
3.30B – 3.30B
+0.9% YoY
|
3.33B
3.33B – 3.33B
+0.9% YoY
|
| Net Income |
1.48B
est: 1.36B (+8.7%)
|
1.70B
est: 1.37B (+24.3%)
|
653.00M
est: 630.79M (+3.5%)
|
1.24B
est: 1.26B (-1.0%)
|
1.85B
est: 1.64B (+13.1%)
|
3.53B
est: 3.05B (+15.9%)
|
2.26B
est: 2.13B (+6.2%)
|
1.67B
est: 1.62B (+2.5%)
|
1.92B
est: 1.73B (+10.9%)
|
1.87B
1.87B – 1.87B
+8.0% YoY
|
1.94B
1.94B – 1.94B
+3.7% YoY
|
| SGA |
11.58B
est: 10.34B (+12.0%)
|
11.47B
est: 10.16B (+12.9%)
|
11.23B
est: 9.82B (+14.4%)
|
11.25B
est: 9.61B (+17.1%)
|
9.52B
est: 9.54B (-0.2%)
|
10.31B
est: 10.98B (-6.1%)
|
10.13B
est: 10.34B (-2.0%)
|
9.34B
est: 9.56B (-2.3%)
|
11.02B
est: 9.52B (+15.8%)
|
9.61B
9.61B – 9.61B
+0.9% YoY
|
9.69B
9.69B – 9.69B
+0.9% YoY
|
| EPS |
133.90
est: 128.00 (+4.6%)
|
156.09
est: 128.60 (+21.4%)
|
59.76
est: 59.40 (+0.6%)
|
116.86
est: 118.20 (-1.1%)
|
178.54
est: 154.30 (+15.7%)
|
338.93
est: 287.10 (+18.1%)
|
215.22
est: 200.50 (+7.3%)
|
151.72
est: 153.00 (-0.8%)
|
181.79
est: 163.00 (+11.5%)
|
176.10
176.10 – 176.10
+8.0% YoY
|
182.70
182.70 – 182.70
+3.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.05% | 192.7K | 0.58% |
| 2 | WisdomTree International Equity Fund DWM | 0.01% | 57.8K | 0.48% |
| 3 | Dimensional - International Small Cap ETF DFIS | 0.00% | 118.6K | 0.39% |
| 4 | iShares Core TOPIX ETF 1475.T | 0.00% | 291.4K | 0.05% |
| 5 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 3.3K | 0.30% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 102.5K | 0.28% |
| 7 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 115.4K | 0.22% |
| 8 | Amundi Japan TOPIX II UCITS ETF EUR Dist JPNU.L | 0.00% | 66.66 | 0.45% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hisayuki Ohba | Executive Officer, GM of Pharma Business Div. & Director | — | male |
| Kei Shimada | Executive Officer & Director | — | male |
| Shuhei Kuroda | Executive Officer & Director | — | male |
| Tadashi Yasuda | President, Executive Officer & Chairman | — | male |
| Takafumi Fukui | Executive Vice President & Director | — | male |
| Tetsuo Goda | GM of Corporate Planning Office & Director | — | male |
| Yoichi Kawata | Managing Executive Officer, GM of Clinical Business Office & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4671.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
